Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
VelosBio Announces First Patient Dosed in Phase 2 Trial of VLS-101 in Solid Tumors
Details : The Phase 2 trial will enroll patients with previously treated solid tumors. Patients will receive VLS-101 2.5 mg/kg intravenously once every three weeks for as long as they are safely benefiting from VLS-101 therapy.
Product Name : VLS-101
Product Type : Antibody
Upfront Cash : Inapplicable
October 19, 2020
Details : Food and Drug Administration (FDA) has granted the company Fast Track and Orphan Drug designation for VLS-101 for the treatment of patients with mantle cell lymphoma (MCL).
Product Name : VLS-101
Product Type : Antibody
Upfront Cash : Inapplicable
August 31, 2020
Details : Oversubscribed funding round to advance the development of investigational, first-in-class antibody-drug conjugates and bispecific antibodies targeting ROR1, a novel oncology target, across multiple cancer types.
Product Name : VLS-101
Product Type : Antibody
Upfront Cash : Undisclosed
August 07, 2020
Details : Acquisition strengthens merck’s oncology pipeline with VLS-101, an investigational antibody-drug conjugate to treat hematological malignancies and solid tumors.
Product Name : VLS-101
Product Type : Antibody
Upfront Cash : $2,750.0 million
May 11, 2020
Reset All
